Trial Profile
A Phase II Study of CFI-400945 and Durvalumab in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Ocifisertib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 10 Dec 2022 Results presented at the 45th Annual San Antonio Breast Cancer Symposium.
- 21 Nov 2022 According to Treadwell Therapeutics media release, data from this study have been accepted for presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS).
- 29 Jun 2022 Planned primary completion date changed from 30 May 2022 to 31 Aug 2022.